Fe 3 O 4 -graphene oxide nanocomposites functionalized with hyaluronic acid and folic acid as dual pH/NIR-responsive platforms for synergistic chemophotothermal therapy of breast cancer

ablate tumor cells and further trigger drug release. This process demonstrated a remarkable synergistic therapeutic efficacy combining photothermal therapy and chemotherapy, achieving a tumor inhibition rate > 90%. When synergistically combined with photothermal therapy, this nanocomposite exhibits significantly enhanced antitumor efficacy against 4T1 tumor-bearing murine models relative to monotherapeutic approaches. This improvement is attributable primarily to its precisely controlled, tumor-targeted drug release mechanism and significantly reduced systemic toxicity. Thus, this study proposed a novel active dual-targeted chemophotothermal therapy (CPT) nanocarrier for targeted cancer therapy.